AMRX Amneal Pharmaceuticals, Inc. Class A Common Stock

$11.58

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/18/2025

About Amneal Pharmaceuticals, Inc. Class A Common Stock

Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.

Website: https://www.amneal.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1723128
Address
,
Valuation
Market Cap
$3.43B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
86.10
Performance
EPS
$-0.38
Dividend Yield
—
Profit Margin
-4.18%
ROE
-881.00%
Technicals
50D MA
$8.15
200D MA
$8.14
52W High
$9.47
52W Low
$5.18
Fundamentals
Shares Outstanding
313M
Target Price
$11.67
Beta
1.07

AMRX EPS Estimates vs Actual

● Estimated
● Actual

AMRX News & Sentiment

Nov 14, 2025 • Zacks Commentary SOMEWHAT-BULLISH
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
Nov 13, 2025 • Benzinga NEUTRAL
Amneal Receives U.S. FDA Approval for Iohexol Injection - Amneal Pharmaceuticals ( NASDAQ:AMRX )
BRIDGEWATER, N.J., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" or the "Company" ) ( NASDAQ:AMRX ) today announced the U.S. Food and Drug Administration ( FDA ) has approved the Company's iohexol injection ( 300 mg Iodine/mL ) , the first generic version of GE ...
Nov 04, 2025 • Zacks Commentary NEUTRAL
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
Oct 30, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Amneal Pharmaceuticals ( AMRX ) Beats Q3 Earnings and Revenue Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +30.77% and +1.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 30, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Amneal Reports Third Quarter 2025 Financial Results
‒ Q3 2025 Net Revenue of $785 million. GAAP Net Income of $2 million. Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million. Adjusted Diluted EPS of $0.17 ‒‒ Updated 2025 Full Year Guidance ...
Oct 29, 2025 • Benzinga NEUTRAL
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol - Amneal Pharmaceuticals ( NASDAQ:AMRX )
BRIDGEWATER, N.J., Oct. 29, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" or the "Company" ) today announced that the U.S.
Sentiment Snapshot

Average Sentiment Score:

0.265
50 articles with scored sentiment

Overall Sentiment:

Bullish

AMRX Reported Earnings

Aug 05, 2025
Jun 30, 2025 (Pre market)
0.08 Surprise
  • Reported EPS: $0.25
  • Estimate: $0.17
  • Whisper: —
  • Surprise %: 47.1%
May 02, 2025
Mar 31, 2025 (Pre market)
-0.11 Surprise
  • Reported EPS: $0.04
  • Estimate: $0.15
  • Whisper: —
  • Surprise %: -73.3%
Feb 28, 2025
Dec 31, 2024 (Pre market)
-0.03 Surprise
  • Reported EPS: $0.12
  • Estimate: $0.15
  • Whisper: —
  • Surprise %: -20.0%
Nov 08, 2024
Sep 30, 2024 (Pre market)
0.03 Surprise
  • Reported EPS: $0.16
  • Estimate: $0.13
  • Whisper: —
  • Surprise %: 23.1%
Aug 09, 2024
Jun 30, 2024 (Pre market)
0.02 Surprise
  • Reported EPS: $0.16
  • Estimate: $0.14
  • Whisper: —
  • Surprise %: 14.3%
May 03, 2024
Mar 31, 2024 (Pre market)
0.05 Surprise
  • Reported EPS: $0.14
  • Estimate: $0.09
  • Whisper: —
  • Surprise %: 55.6%
Mar 01, 2024
Dec 31, 2023 (Pre market)
0.05 Surprise
  • Reported EPS: $0.14
  • Estimate: $0.09
  • Whisper: —
  • Surprise %: 55.6%
Nov 07, 2023
Sep 30, 2023 (Pre market)
0.06 Surprise
  • Reported EPS: $0.19
  • Estimate: $0.13
  • Whisper: —
  • Surprise %: 46.1%
Aug 04, 2023
Jun 30, 2023 (Pre market)
0.08 Surprise
  • Reported EPS: $0.19
  • Estimate: $0.11
  • Whisper: —
  • Surprise %: 72.7%

Financials